Chapter 56: Neurological Medications

The discussion progresses to multiple sclerosis therapeutics, including immunomodulatory agents such as interferons and glatiramer acetate that slow disease progression, alongside immunosuppressants like mitoxantrone that carry risks of hepatotoxicity and bone marrow suppression. Parkinson's disease treatment centers on dopamine replacement strategies, primarily carbidopa-levodopa combinations with timing considerations relative to protein intake, anticholinergic medications to reduce tremor and rigidity, and catechol-O-methyltransferase inhibitors that extend dopamine availability. The chapter extensively covers anticonvulsant medications organized by chemical class, including hydantoins with characteristic gingival hyperplasia and narrow therapeutic windows, barbiturates requiring monitoring for sedation and dependence, benzodiazepines with rapid seizure control, succinimides and valproates with distinct adverse effect profiles, and carbamazepine with significant hematologic and visual complications. Additional sections address central nervous system stimulants for attention deficit hyperactivity disorder, nonsteroidal anti-inflammatory drugs with gastrointestinal and bleeding considerations, acetaminophen with hepatotoxic potential at elevated doses, opioid analgesics requiring respiratory and constipation monitoring, opioid antagonists like naloxone for overdose reversal, and osmotic diuretics such as mannitol for intracranial pressure management and glaucoma. Throughout, nursing interventions emphasize medication timing, adverse effect recognition, client education regarding medication adherence and safety precautions, and critical monitoring parameters essential for safe therapeutic outcomes.